|
|
|
News Room |
October 2010: East West Capital Partners has entered into an agreement with a European Family office to jointly Manage and Fund a cancer drug delivery company.
The strategy is to de-risk and accelerate the development of a novel third-generation liposomal delivery technology by shifting the manufacturing and conducting the later stage clinical validation in India.
Covered by a strong patent portfolio, the Company is expected to seek approval across a range of oncology drugs for targeted therapeutic delivery to solid tumors with much reduced side effects and therefore an improved therapeutic ratio.
The investment exemplifies a core EWCP belief that Intellectual Property can be commercialized in an affordable and expedient way by active cross-border development of IP (typically generated in the developed world) using existing infrastructure available in emerging markets.
For confidentiality reasons, specific names and amounts have been withheld.
About East West Capital Partners
EAST WEST CAPITAL PARTNERS (“EWCP”) is a private equity advisory firm operating out of Singapore, Bangalore, Penang and London. EWCP seeks to invest only in the life sciences and healthcare industry, i.e., pharmaceuticals, biotech, medical technology and devices, healthcare services, hospitals/clinics, drug discovery services and healthcare IT. The EWCP team consists of professionals from the healthcare and investment industry, cumulatively with close to 100 years of global experience. For more information,please see www.eastwestcap.com
For more information, please contact: Sanjay Sehgal, Managing Partner & CEO at sanjay@eastwestcap.com or Duncan Moore, Partner at duncan@eastwestcap.com
|
|
|
|
|
|
|
